|View printer-friendly version|
|US Food and Drug Administration (FDA) Begins Scientific Review of Philip Morris International’s Modified Risk Tobacco Product Application for its Electronically Heated Tobacco Product (EHTP)|
PMI submitted the application to the
Publication of PMI’s summaries initiates a substantive scientific review
process by the FDA’s
Interested members of the scientific and public health communities can find more information on PMI’s EHTP at: PMIScienceUSA.com.
PMI is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of reduced-risk products (“RRPs”). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.